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Exosomopathies are a collection of rare diseases caused by mutations in genes that encode structural subunits of the 
RNA exosome complex (EXOSC). The RNA exosome is critical for both processing and degrading many RNA targets. 
Mutations in individual RNA exosome subunit genes (termed EXOSC genes) are linked to a variety of distinct diseases. 
These exosomopathies do not arise from homozygous loss-of-function or large deletions in the EXOSC genes likely 
because some level of RNA exosome activity is essential for viability. Thus, all patients described so far have at least 
one allele with a missense mutation encoding an RNA exosome subunit with a single pathogenic amino acid change 
linked to disease. Understanding how these changes lead to the disparate clinical presentations that have been reported 
for this class of diseases necessitates investigation of how individual pathogenic missense variants alter RNA exosome 
function. Such studies will require access to patient samples, a challenge for these very rare diseases, coupled with 
modeling the patient variants. Here, we highlight five recent studies that model pathogenic variants in EXOSC3, 
EXOSC2, and EXOSC5. 
Keywords: RNA exosome; exosomopathies; EXOSC3; EXOSC2; EXOSC5; Pontocerebellar Hypoplasia 
To cite this article: Julia de Amorim, et al. Modeling Pathogenic Variants in the RNA Exosome. RNA Dis 2020; 7: e1166. 
doi: 10.14800/rd.1166. 
Abbreviations: RNA, ribonucleic acid; EXOSC, exosome component; PCH, pontocerebellar hypoplasia; SHRF, short stature, 
hair loss, retinitis pigmentosa, distinct facies; rRNA, ribosomal RNA; snRNA, small nuclear RNA; snoRNA, small nucleolar 
RNA; tRNA, transfer RNA; CUTs, cryptic unstable transcripts; PROMPTs, promoter upstream transcripts; mRNA, messenger 




The RNA exosome is a 10-subunit complex responsible 
for essential RNA processing and degradation in both the 
cytoplasm and the nucleus (Figure 1). The ribonuclease 
activity of the RNA exosome is critical for both RNA 
quality control and precise processing of key RNAs, 
including ribosomal RNA (rRNA) [1]. As shown in Figure 
1, the 10 subunits of this complex are organized into a non-
catalytic cap composed of three subunits (EXOSC1-3), a 
barrel-shaped non-catalytic core composed of six subunits 
(EXOSC4-9), and one catalytic 3′-5′ exo/endoribonuclease 
subunit that sits at the base of the core (DIS3) [2-6]. Most 
target RNAs are threaded through the cap and the central  
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Figure 1. Pathogenic missense variants in structural subunits of the RNA exosome cause human disease with 
diverse clinical presentations. A) The domain structures of EXOSC2, EXOSC3, and EXOSC5 are shown. Sequence 
alignments of human (H. sapiens), mouse (M. musculus), zebrafish (D. rerio), fruit fly (D. melanogaster), and yeast 
(S. cerevisiae) orthologs are depicted below the structures to highlight the conserved residues altered in disease and 
the flanking conserved regions. Numbers preceding the sequences indicate the amino acid position and the red arrows 
above the domain structures indicate the approximate location of the respective amino acid substitution. The overall 
percent identity of the EXOSC orthologs compared to human EXOSC proteins is shown to the right of the sequence 
alignments. B) A cartoon rendering of the human RNA exosome is shown on the left and a structural model of the 
complex (PDB #6D6Q) is displayed on the right. The cap (EXOSC1-3), the core (EXOSC4-9), and the catalytic 
exo/endoribonuclease (DIS3) are labeled and the EXOSC2 (yellow), EXOSC3 (green), and EXOSC5 (blue) subunits 
altered in disease are highlighted. 
 
 
channel of the barrel to reach DIS3 for processing and/or 
degradation [7, 8]. The RNA exosome is evolutionarily 
conserved, and all subunits analyzed are essential in any 
model organisms where studies have been performed [9-
16].  
Genes encoding subunits of the RNA exosome complex 
were initially discovered in a genetic screen for rRNA 
processing mutants in budding yeast [1, 17]. Studies in S. 
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cerevisiae demonstrate that 1) each subunit is essential for 
survival, 2) the RNA exosome processes and degrades 
target transcripts in a 3’-5’ orientation, and 3) conditional 
mutations in genes encoding the RNA exosome subunits 
impair RNA metabolism [1, 13, 17, 18]. Early structures of 
the RNA exosome from a number of organisms provided 
key insight into how this complex could process and decay 
RNA [19-21]. Since then, a number of both structural and 
in vitro biochemical studies have been employed to 
understand the many functions of this critical complex [22, 
23]. The RNA exosome regulates/processes several classes 
of RNAs in different cellular compartments [24-27]. In the 
nucleolus, RNA exosome-mediated processing is essential 
for the production of mature rRNA [24]. Within the nucleus, 
this complex also processes and/or degrades small nuclear 
RNAs (snRNAs), small nucleolar RNAs (snoRNAs), 
tRNAs, cryptic unstable transcripts (CUTs) in yeast, and 
promoter-upstream transcripts (PROMPTs) in mammals 
[18, 25, 28-30]. In the cytoplasm, key targets include 
normal mRNAs in the turnover pathway and aberrant 
mRNA transcripts, such as those lacking a stop codon, in 
quality control pathways [31]. In addition, the RNA 
exosome regulates the levels of a variety of different 
transcripts [2, 24, 25]. To recognize and process/degrade 
distinct targets, the RNA exosome interacts with cofactors, 
proteins that associate with the complex [2]. Several RNA 
exosome cofactors that serve as RNA helicases, scaffolds, 
additional ribonucleases, and polyadenylases have been 
described [2, 5-7, 28, 32-35]. Cofactors have been primarily 
characterized in budding yeast, but more recent studies 
have identified mammalian cofactors [2, 27, 36, 37], 
providing fundamental insights into RNA exosome 
specificity for processing and decay of target RNAs.  
Pathogenic missense variants in subunit genes of the 
RNA exosome are linked to disease. 
Although the function of the RNA exosome is essential 
[17, 38], a number of studies have now identified mutations 
in genes encoding structural subunits of this complex linked 
to diverse clinical presentations (Table 1). These diseases 
are termed exosomopathies [10]. The initial report linking 
RNA exosome genes to disease described several 
pathogenic variants in EXOSC3 that cause pontocerebellar 
hypoplasia type 1b (PCH1b) [16]. Subsequent studies 
linked EXOSC2 [39], EXOSC8 [9], EXOSC9 [10], and 
EXOSC5 [40] to a variety of clinical presentations [41]. 
Although the clinical presentations of exosomopathies 
are variable, impacts on the cerebellum are a common 
feature. In four of the five exosomopathies described to date, 
patients present with abnormal development of the 
cerebellum (cerebellar hypoplasia or pontocerebellar 
hypoplasia) or degeneration of the cerebellum. The 
cerebellar pathology is quite diverse and is typically 
associated with additional clinical manifestations [41]. 
Mutations in EXOSC3 give rise to PCH1b, a disease 
characterized by atrophy of the cerebellum and the pons [16, 
42]. EXOSC8 mutations cause pontocerebellar hypoplasia 
type 1 c (PCH1c), characterized by hypomyelination with 
spinal muscular atrophy and cerebellar hypoplasia [9]. 
EXOSC9 mutations give rise to pontocerebellar hypoplasia 
type 1 d (PCH1d), a spinal motor neuronopathy coupled 
with cerebellar atrophy [10, 43]. While only a few patients 
with mutations in EXOSC5 have been described, these 
patients also show cerebellar abnormality as a common 
clinical feature [40]. In contrast to the other EXOSC 
mutations, pathogenic variants in EXOSC2 only cause 
mild/borderline cerebellar atrophy and patients present with 
short stature, hearing loss, retinitis pigmentosa, and 
distinctive facies (denoted as SHRF) [39]. Whether the 
cerebellar hypoplasia and atrophy observed in the 
exosomopathies are part of a clinical spectrum that results 
from the same pathological process and molecular 
mechanism or distinct manifestations is still unknown. 
Little is understood about why these pathogenic 
missense variants in genes encoding structural subunits of 
an essential complex that is ubiquitously expressed give 
rise to a broad range of clinical presentations. All patients 
with exosomopathies described thus far have at least one 
missense variant in an EXOSC gene (Table 1) [41]. Some 
patients are homozygous for the same missense variant, 
others are compound heterozygous for different missense 
variants, and some patients have a missense variant 
inherited in trans to a deletion or loss-of-function variant. 
The complete loss of the RNA exosome is lethal [9-16]; 
therefore, the missense variants likely provide residual 
RNA exosome function in all patients. These specific 
variants in different EXOSC genes may underlie the 
disparate clinical presentations of patients. The pathogenic 
amino acid changes could alter the function of individual 
subunits or the integrity of the RNA exosome complex, 
ultimately affecting downstream RNA targets.  
Studies to define the molecular mechanisms underlying 
pathology in exosomopathies have used several approaches: 
1) immortalized patient cells, 2) deletion or depletion of the 
affected EXOSC gene, and 3) modeling of the pathogenic 
missense variants in either model genetic systems or 
cultured cells. Ultimately, understanding how defects in 
RNA exosome function contribute to disease pathology 
will require studies investigating how the pathogenic amino 
acid substitutions impact the function of the complex. At 
this time, in vivo studies that model missense mutations to 
understand how disease-linked amino acid changes could 
alter RNA exosome function have employed budding yeast 
and Drosophila melanogaster. Here, we highlight recent  
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EXOSC1     
EXOSC2 
Homozygous G30V SHRF [39]ii     
Heterozygous G30V/G198D SHRF   iii  
EXOSC3 
Homozygous D132A PCH1b [16, 54]   
  
Homozygous G31A PCH1b    
 
Homozygous G191C PCH1b     
Heterozygous G31A/W238R PCH1b iv 
 v  
Heterozygous D132A/delvi PCH1b  
 
  
EXOSC4     
EXOSC5 
Homozygous L206H Novel exosomopathy [40]     
Homozygous M148T Novel exosomopathy      
Heterozygous T114I/delvi Novel exosomopathy     
EXOSC6     
EXOSC7     
EXOSC8 
Homozygous S272T PCH1c [9]     
Homozygous A2V PCH1c     
EXOSC9 Homozygous L14P PCH1d [46]     
 D. melanogaster 
 S. cerevisiae 
 Cultured cell lines 
 Patient samples/cultured patient cells 
iHomozygous or compound heterozygous 
iiShort stature, hair loss, retinitis pigmentosa, distinct facies (SHRF) 
iiiHEK293T cells were transfected with either the EXOSC2 G30V or the EXOSC2 G198D variant. 
ivHaploid budding yeast either expressed the yeast variant corresponding to EXOSC3 G31A or EXOSC3 W238R.  
vNeuro2A cells were transfected with the variant corresponding to either EXOSC3 G31A or EXOSC3 W238R. 
viGenetic deletion 
 
studies that model pathogenic missense variants in 
EXOSC3 [11, 12, 14], EXOSC2 [15] and EXOSC5 [40].  
EXOSC3 mutations impair RNA exosome function and 
organism viability. 
Initial studies to explore the functional consequences of 
pathogenic variants in EXOSC3 employed the budding 
yeast model system [11, 12]. The first observation from 
these studies is that pathogenic variants in EXOSC3 
modeled in yeast did not severely impact yeast cell growth 
or viability. This result is perhaps not surprising as each 
subunit of the RNA exosome is essential in the systems 
where this has been tested [1, 9-16, 44]. The presumption 
is that changes that significantly impair the function of this 
essential complex, which might impart a growth defect in 
yeast cells, may not be compatible with the human 
developmental program. 
Although severe growth defects were not observed, both 
these studies showed that the yeast EXOSC3 variant 
corresponding to EXOSC3 W238R (W195R in yeast 
EXOSC3) conferred a temperature-sensitive growth defect 
when expressed as the sole copy of yeast EXOSC3 [11, 12]. 
Moreover, these cells showed a significant impact on RNA 
processing and degradation mediated by the RNA exosome. 
Yeast EXOSC3 variants corresponding to EXOSC3 G31A 
(G8A in yeast EXOSC3), G191C (G148C in yeast 
EXOSC3), and W238R (W195R in yeast EXOSC3), 
showed impaired rRNA processing with the most profound 
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effects evident for the yeast W195R variant [11]. Fasken et 
al. also observed misprocessing and accumulation of 
several RNA exosome targets, including CUTs and pre-
snRNA, in cells expressing the W195R variant as the sole 
copy of yeast EXOSC3 [12]. In contrast, no effect on 
cytoplasmic RNA exosome function was detected [12]. The 
yeast model studies thus indicate that the W195R variant 
impairs cell function and significantly hinders RNA 
processing, suggesting that the EXOSC3 W238R variant is 
quite deleterious. This allele has only been identified in the 
compound heterozygous state in patients [16, 42], raising 
the possibility that EXOSC3 W238R may not confer 
sufficient RNA exosome activity to support life as a 
homozygous variant. 
To begin to address how pathogenic amino acid 
substitutions could impair RNA exosome function, one 
study compared both the steady-state levels and stability of 
the yeast EXOSC3 variants to the wild-type protein [12]. 
Results of this analysis demonstrated that the yeast W195R 
variant protein is unstable when expressed as the sole copy 
of the yeast EXOSC3 protein and becomes further 
destabilized under conditions where a wild-type copy of the 
subunit is also present. These results suggest that perhaps 
the pathogenic subunits are not as efficiently incorporated 
into the complex as the wild-type subunits, or once 
pathogenic subunits are incorporated, the complex is not as 
stable. These yeast studies were complemented by 
analyzing mouse EXOSC3 variant protein levels in 
cultured mouse neuronal cells. This analysis showed that 
the steady-state level of the mouse EXOSC3 protein 
modeling the W238R variant is reduced in these cells 
compared to wild-type EXOSC3 [12]. Thus, a decrease in 
overall complex level could contribute to pathology in 
exosomopathies, as suggested from analyses of other 
EXOSC variants, such as EXOSC9 [10]; however, it is 
difficult to reconcile the very diverse clinical presentations 
of these diseases with a simple loss of or decrease in overall 
complex function.  
Beyond affecting protein levels, pathogenic amino acid 
substitutions could also alter key interactions with other 
RNA exosome subunits or with the associated cofactors. 
Indeed, one study demonstrated that the yeast EXOSC3 
W195R variant corresponding to EXOSC3 W238R shows 
decreased affinity for a cofactor, Mpp6 (MPHOSPH6 in 
humans), compared to wild-type yeast EXOSC3 [6]. These 
results support a model where altered interactions with 
RNA exosome cofactors could contribute to disease 
pathology.  
Studies modeling pathogenic variants in EXOSC3 have 
been extended to Drosophila. This system enables the 
effects of the EXOSC3 variants on the nervous system and 
brain to be studied within a genetically tractable system. A 
previous study in Drosophila demonstrated that RNA 
exosome subunits are essential in flies [45], consistent with 
the results obtained in budding yeast [1]. In the present 
study, CRISPR/Cas9 genome editing was used to engineer 
pathogenic variants of EXOSC3 into the Drosophila 
genome [14]. This is the first study that analyzes RNA 
exosome mutations recapitulated at the genome level in a 
multi-tissue organism. The study modeled three patient 
genotypes [16, 42]: homozygous G31A, homozygous 
D132A, and D132A over a deficiency to model patients 
heterozygous for the D132A pathogenic variant  inherited 
in trans to a deletion in EXOSC3. Results of this analysis 
show a striking genotype-phenotype correlation with 
respect to fly viability, lifespan, and locomotor function. 
The pathogenic variants that are most severe in patients [46] 
correlate with those that cause the most striking phenotypes 
in flies.  
These mutant EXOSC3 flies show morphological defects 
in the mushroom body, the area of the fly brain that controls 
learning and memory [47], that also correlate with the 
severity of the different EXOSC3 alleles modeled. Finally, 
RNA sequencing of the heads of these mutant flies revealed 
an increase in the steady-state levels of a number of 
important neuronal transcripts, a result that is consistent 
with the role of this complex in RNA decay. This study 
developed a multi-cellular model to explore the 
consequence of pathogenic RNA exosome variants and 
provided insight into target RNAs affected in this model 
[14]. 
SHRF-causing pathogenic variants in EXOSC2. 
Mutations in EXOSC2 give rise to a novel syndrome 
characterized by short stature, hair loss, retinitis 
pigmentosa, and distinctive facies (SHRF) [39]. A recent 
study combined analysis of patient samples, biochemical 
approaches, and studies in Drosophila to explore the 
functional consequences of pathogenic missense variants in 
EXOSC2 [15]. Biochemical analyses of both patient cells 
and transfected cell lines demonstrated that the G198D 
variant, but not the G30V variant, affects EXOSC2 protein 
stability and interactions with other RNA exosome 
components. While these authors did not create a fly model 
of the pathogenic variants in EXOSC2, they did test whether 
the EXOSC2 G30V variant could rescue defects observed 
in the eye in rare “escapers” where fly EXOSC2 was deleted. 
The eye defect was partially rescued when the human wild-
type EXOSC2 gene was expressed, but not the pathogenic 
variant, providing evidence that EXOSC2 G30V does not 
retain the function of wild-type EXOSC2 [15]. RNA-
sequencing on patient samples identified several 
dysregulated autophagy pathway genes [15]. In addition, in 
patient-derived B-lymphoblast cells with mutations in 
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EXOSC2, overall RNA exosome subunit abundance is 
reduced and EXOSC2 proteins are unstable [15]. These 
findings are consistent with other studies that show a 
decrease in RNA exosome subunit levels in patient-derived 
samples [10], but do not readily explain why patients with 
mutations in different EXOSC genes display such a variety 
of clinical presentations. 
Novel EXOSC5 mutations impair RNA exosome activity. 
A recent study reported five patients with biallelic 
variants in the EXOSC5 gene [40]. Three of the four 
patients who learned to walk demonstrated ataxia, and four 
of the five patients’ brain imaging showed hypoplasia of the 
cerebellum or cerebellar vermis [40]. This study employed 
three approaches to examine the link between EXOSC5 and 
disease pathology; two of these approaches modeled the 
pathogenic variants that have been identified in EXOSC5. 
The initial approach employed zebrafish to assess the 
requirement for EXOSC5 in neurodevelopment has also 
been employed for the analysis of EXOSC3 [16], EXOSC8 
[9], and EXOSC9 [10]. The CRISPR-Cas9 system was 
employed to generate an allele with predicted loss of 
EXOSC5 function. Consistent with previous studies of 
other RNA exosome subunit genes, zebrafish lacking 
EXOSC5 showed profound growth, developmental, and 
brain morphology defects [40]. To extend this analysis and 
explore the functional consequences of pathogenic variants 
in EXOSC5, the missense variants identified in EXOSC5 
(I114T, M148T, and L206H) were all modeled in budding 
yeast. Only the yeast EXOSC5 variant corresponding to 
EXOSC5 L206H (L191H in yeast EXOSC5) showed 
growth defects, manifested as temperature-sensitive growth. 
Immunoblotting showed no statistically significant change 
in yeast EXOSC5 protein levels for any of these variants. 
Consistent with the growth defect observed, the yeast 
variant corresponding to EXOSC5 L206H showed defects 
in U4 snRNA and 7S pre-rRNA processing [40]. 
Biochemical studies in cultured mouse neuronal cells were 
performed to explore the interactions of mouse EXOSC5 
variants with other subunits of the RNA exosome. 
Interestingly, the EXOSC5 L206H and I114T variants 
showed a decreased interaction with multiple other subunits 
of the complex. No defect in interaction was detected for 
the EXOSC5 M148T raising the question of how this amino 
acid substitution contributes to pathology.  
Conclusions and Future Perspectives 
The model organisms used to study RNA exosome 
biology have shed light on the complicated cellular roles of 
this multi-functional protein complex. Thus far, pathogenic 
missense variants in EXOSC genes that encode RNA 
exosome subunits have been linked to diverse clinical 
presentations with the majority causing some degree of 
cerebellar hypoplasia and/or atrophy. These EXOSC 
variants appear to have tissue-specific consequences. An 
ideal system to further explore the consequences of these 
pathogenic variants would be in an affected patient tissue 
or cultured primary cells. These samples are difficult to 
obtain because the disease is rare with only small numbers 
of patients identified to date. The cerebellum consists 
largely of Purkinje and granule cells [48]; therefore, an 
ideal in vitro system would be a genome-edited cerebellar 
cell-type organoid because the three-dimensional shape 
allows for multiple cell types. In vivo studies in model 
organisms thus far have allowed for simple recapitulation 
of pathogenic variants. Budding yeast are advantageous 
because they are simple to use and multiple functions of the 
conserved RNA exosome complex can be readily assayed. 
However, yeast lack relevant cell or tissue types. 
Drosophilae are multi-tissue organisms with a complex 
nervous system and a brain, which have been used 
extensively to model human disease [49]. However, fly 
brain structures lack elements of the human brain and some 
neurons are not well conserved [50].   
A mammalian system would provide further insight into 
how specific pathogenic amino acid variants alter the 
function of the RNA exosome and cause diverse biological 
changes that underlie pathology. Thus far, no whole 
organism mouse models for mutations in any RNA 
exosome gene have been described. One study employed 
an ex vivo approach to swap exons 2 and 3 within EXOSC3 
in B cells [51]. The authors exploited this ex vivo system to 
explore the downstream effects of the loss of this RNA 
exosome subunit in B cells and identify key RNA exosome 
targets in this cell type [51]. A transgenic mouse that uses 
genome editing to incorporate pathogenic missense variants 
of EXOSC genes into the genome would greatly advance 
research in this field. Currently, the Jackson Laboratory site 
[52] lists CRISPR-generated knockout mouse strains for 
EXOSC1 and EXOSC2, but there are no reports of 
researchers attempting to derive or analyze these strains. 
A proposed model suggests that depletion of a subunit in 
model organisms recapitulates the patient disease because 
immunoblots of patient fibroblasts, myoblasts, and skeletal 
muscle samples show an overall steady-state decrease in 
protein levels of the affected subunits and other subunits in 
the complex [9, 10]. However, this model is difficult to 
reconcile with patients that show variable clinical 
presentation. Some of the EXOSC pedigrees identified to 
date also call into question whether the primary driver of 
pathology is a decrease in RNA exosome subunit or 
complex levels. Several of the pedigrees for patients 
include seemingly unaffected parents with presumed loss 
of function of one EXOSC allele [16, 40, 41, 46]. Consistent  
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Figure 2. A proposed model of how pathogenic missense variants in EXOSC genes could contribute to 
variation in clinical presentation. The RNA exosome interacts with specific cofactors to confer specificity 
for target transcripts (left). Most cofactors have been identified and studied in budding yeast or cultured cells. 
Different pathogenic variants in structural subunits of the RNA exosome could disrupt interactions with a 
subset of cofactors. These cofactors could be critical in the cerebellum or other tissues susceptible to 
pathology. Interestingly, the four genes that encode RNA exosome subunits that include cerebellar atrophy 
and/or hypoplasia as a major clinical component, EXOSC3, EXOSC5, EXOSC8, and EXOSC9 are present 
on one face of the complex. In contrast, the cap subunit, EXOSC2 is located on the opposite side of the 
complex. Thus, loss of interactions with specific cofactors could contribute to the variable symptoms 
described in SHRF. 
 
with this idea, flies heterozygous for a deficiency that 
removes the Drosophila EXOSC3 gene do not show any of 
the phenotypes noted in the disease model flies [14]. These 
flies appear similar to wild-type flies in all assays 
performed, showing that even with presumably only 50% 
of expression of the EXOSC3 gene, no phenotype is 
detected. Likely, pathology results from some combination 
of a decrease in overall RNA exosome levels and 
consequences of the specific pathogenic variants present. 
Further studies that examine the pathogenic missense 
variants of the EXOSC genes as well as the full RNA 
exosome complex are required to fully understand the 
molecular defects that contribute to pathology. 
Experimental systems that deplete or delete an EXOSC 
gene provide critical insight but also simplify a more 
complex story. A major challenge remains understanding 
why the clinical presentation of patients with mutations in 
genes that encode a single complex show such variable 
pathology with some overlapping, but some distinct tissues 
affected. At the mechanistic level, pathogenic amino acid 
changes could, and certainly do [10], decrease the overall 
levels of the individual RNA exosome subunit and/or the 
complex. The changes might also alter the function of the 
complex at a molecular level, disrupting RNA binding or 
interactions with other subunits or cofactors. Moreover, 
certain cell types may express specific RNA exosome 
cofactors that interact and stabilize the RNA exosome, 
whereas other affected tissues may not express these 
cofactors (Figure 2). Loss of interactions with these 
cofactors could contribute to altered stability of the 
complex or changes in target specificity. These potential 
mechanistic consequences would all affect exosome-
mediated RNA processing/decay.  
New pathogenic EXOSC alleles are being reported by 
physicians worldwide. To date, pathogenic variants in 
EXOSC1, EXOSC4, EXOSC6, and EXOSC7 have not been 
reported (Table 1); however, this is likely to change. 
GeneMatcher®, a freely available website designed to 
enable connections between clinicians and researchers [53], 
will likely continue to lead to identification of new alleles 
in these genes and in new genes as recently illustrated in the 
collaborative study of EXOSC5 [40]. As additional 
pathogenic variants are identified, this could provide 
insight into whether there is a common mechanism 
underlying pathology. A combination of approaches that 
includes functional studies in model organisms and analysis 
of patient samples will be critical to understand the 
mechanisms that underlie pathology. Further insight into 
the molecular consequences of single amino acid changes 
in EXOSC genes via genome-edited model systems will be 
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required to paint the full canvas of RNA exosome biology 
and disease. 
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